Meeting
2014 Genitourinary Cancers Symposium
In vitro reproduction and explanation of an abiraterone acetate withdrawal phenomenon.
Authors
Paul Thelen
Georg-August-University, Göttingen, Germany
Paul Thelen , Hubertus Jarry , Lutz Trojan , Sabine Brookman-May , Felix Bremmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 154)
DOI
10.1200/jco.2014.32.4_suppl.154
Abstract #
154
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin
Poster
2013 Genitourinary Cancers Symposium
Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC).
First Author: Paul Thelen
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.
First Author: Benjamin H Lowentritt
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli